Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Colorectal Neoplasms 1

Interventions

Cisplatin 5Carboplatin 5pembrolizumab 4Cyclophosphamide 4Bevacizumab 4130-nm albumin-bound paclitaxel 4Oxaliplatin 3Magnetic Resonance Spectroscopy 3Leucovorin 3Irinotecan 3Gemcitabine 3Fluorouracil 3Docetaxel 3Capecitabine 3tislelizumab 2fludarabine 2Specimen Handling 2Riluzole 2Quality of Life 2Psychiatric Rehabilitation 2Oncolytic Virotherapy 2Observation 2Fluorodeoxyglucose F18 2Fluorescein 2Floxuridine 2Filgrastim 2Drug Therapy 2Cetuximab 2umbralisib 1trifluridine tipiracil drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × umbralisib × Sarcoma × Clear all
NCT02574663 2019-10-02

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

TG Therapeutics, Inc.

Phase 1 Completed
66 enrolled
GastrointestinalSarcoma

Esophageal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡